Published January 1, 2022
| Version v1
Journal article
Open
Sultam based Carbonic Anhydrase VII inhibitors for the management of neuropathic pain
Creators
- 1. Ege Univ, Fac Pharm, Dept Pharmaceut Chem, TR-35100 Izmir, Turkey
- 2. Univ Firenze, NEUROFARBA Dept, Sect Pharmacol & Toxicol, Viale Pieraccini 6, I-50139 Florence, Italy
- 3. CNR, Inst Biostruct & Bioimaging, Via Mezzocannone 16, I-80134 Naples, Italy
- 4. Univ Firenze, NEUROFARBA Dept, Sez Sci Farmaceut & Nutraceut, Via Ugo Schiff 6, I-50019 Sesto Fiorentino, Italy
Description
We report a series of compounds 1-17 derived from the antiepileptic drug Sulthiame (SLT) from which both the benzenesulfonamide and the sultam moiety were retained. All compounds were tested in vitro for their inhibition activity against the human (h) Carbonic Anhydrase (CA; EC 4.2.1.1) I, II, VII, IX and XII isoforms. Among the series, derivatives 1 and 11 showed great enhancement of both inhibition potency and selectivity towards the hCA VII isoform, when compared to the reference SLT drug. The binding mode of 11 within the hCA VII active site was deciphered by means of X-ray crystallography and revealed the sultam moiety being exposed to the rim of the active site. In vivo experiments on a model of neuropathic pain induced by oxaliplatin clearly showed 11 being an effective pain relieving agent and therefore worth of further exploitation towards the validation of the hCA VII as new target for the management of neuropathies. (C) 2021 Elsevier Masson SAS. All rights reserved.
Files
bib-5945645a-4e47-4c88-b2e6-4ddf087d8969.txt
Files
(293 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:47452ff496e79de5b417f7c93d9059b7
|
293 Bytes | Preview Download |